This monoclonal antibody specifically targets ICAM-1 while preserving its adhesion capabilities, making it a versatile tool for diverse research and diagnostic procedures. Features include its use in immunohistochemistry, western blotting, immunoprecipitation, and flow cytometry. Detailed studies revealed that its F(ab')2 fragments are particularly adept at detecting malignant lesions, with sensitivity enhanced by interferon-gamma in tumor xenografts. Developed using a hybridoma cell line originally from New York Medical College and refined at the University of Pittsburgh, this antibody is designed to accurately visualize ICAM-1 expression without disrupting cell adhesion processes.
Description
The technology stands apart due to its non-inhibitory binding, a critical differentiator from other antibodies targeting ICAM-1. This selective approach avoids interference with natural cell adhesion, ensuring that diagnostic and analytical outcomes are not compromised. Additionally, its enhanced performance in detecting malignant lesions – especially under conditions of interferon-gamma enhancement – highlights its potential for improved immunoscintigraphy and targeted immunotherapy. Its unique sensitivity profile, influenced by tumor size, underscores significant promise for advancing both clinical diagnostics and research methodologies.
Applications
- Immunohistochemistry diagnostic reagent
- Western blot detection reagent
- Flow cytometry analysis reagent
- Radiolabeled immunoscintigraphy agent
- Immunoprecipitation research tool
Advantages
- Maintains ICAM-1’s natural adhesion function, allowing its detection without disrupting cell adhesion processes.
- Enhances the sensitivity of malignant lesion detection using F(ab')2 fragments, especially after IFN-γ stimulation.
- Supports versatile applications in immunohistochemistry, western blotting, immunoprecipitation, and flow cytometry.
- Improves the accuracy of tumor imaging and potential immunoscintigraphy through size-dependent targeting.
IP Status
Research Tool
